Same Indication

Ipilimumab vs Rivaroxaban

Ipilimumab vs Rivaroxaban: Overview

This comparison examines the pharmacological differences between Ipilimumab and Rivaroxaban.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Rivaroxaban: Direct Factor Xa inhibitor.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days; Rivaroxaban β€” 5-9 hours.

Chemical Properties

Molecular Formula: Rivaroxaban β€” C19H18ClN3O5S.

Molecular Weight: Rivaroxaban β€” 435.8820 g/mol.

Type: Ipilimumab β€” Antibody; Rivaroxaban β€” Small molecule.